Weekly updateCompaniesRecruiting servicePost a job
Kinevant Sciences

Kinevant Sciences

    Company info:

  • 1-50
  • 2018
  • New York, NY
  • not disclosed



Claim company profile

About company:

Kinevant Sciences is developing new therapies for rare inflammatory and autoimmune diseases. Cytokines are small proteins that regulate the immune system and play a role in driving many inflammatory diseases. Many cytokines are already validated as targets for treating inflammatory diseases, and Kinevant is further expanding the potential. Kinevant’s lead candidate, namilumab, is a novel monoclonal antibody being developed for pulmonary sarcoidosis treatment. Namilumab targets a key pro-inflammatory cytokine involved in the disease, GM-CSF, and has been demonstrated to be well-tolerated in multiple clinical trials. Plans are in place to start Phase 2 trials in patients soon.


Claim company profile to post jobs directly on this page and this website.

© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com